Current Report Filing (8-k)
02 Mars 2022 - 11:16PM
Edgar (US Regulatory)
false 0000876378 0000876378 2022-02-28
2022-02-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 28, 2022
Date of Report (date of earliest event reported)
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
0-19437
(Commission
File Number)
|
|
11-2962080
(I.R.S. Employer
Identification Number)
|
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
|
Common Stock
$0.001 par value per share
|
|
ASXC
|
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 2.02
|
Results of Operations and Financial Condition
|
On February 28, 2022, Asensus Surgical, Inc., a Delaware
corporation (the “Company”), issued a press release announcing its
financial results for the fourth quarter and full year ended
December 31, 2021. A copy of the press release is furnished
herewith as Exhibit 99.1.
Also on February 28, 2022, following the issuance of the press
release referred to above, the Company conducted a conference call
to discuss the reported operating and financial results for the
fourth quarter and full year ended December 31, 2021. The Company
had issued a press release on February 22, 2022 to announce the
scheduling of the conference call. A copy of the transcript of the
conference call is furnished herewith as Exhibit 99.2.
The information included herein and in Exhibit 99.1 and Exhibit
99.2 shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (“Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933 or the Exchange Act, except as expressly set forth by specific
reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
ASENSUS SURGICAL,
INC.
|
|
|
|
|
Date: March 2,
2022
|
/s/ Shameze
Rampertab
|
|
|
Shameze
Rampertab
|
|
|
Executive Vice
President and Chief Financial Officer
|
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023
